Abstract: Compounds having activity as inhibitors of ENPP1, CdnP, or both are provided herein. Some embodiments provide compounds having one of the following Structures (I) or (II): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein R1, R2, R3, R4, R5, R6, R7a, R7b, R7b, R7c, R25, R26, R27a, R27b, R27c, L1, L5, L6, G1, G2, G3 and G6 are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating disorders associated with ENPP1, including uncontrolled cellular proliferation, cancer and virial or bacterial infections in a mammal.

Abstract: The present invention relates to a system for secure deployment of microservice instance over load-balanced kubernetes, and a method thereof. The system and method facilitates the secure deployment and orchestration of microservice instances and web services on load-balanced Kubernetes containers across diverse Cloud Service Providers' (CSPs) Infrastructure as a Service (IAAS) environments. The present invention addresses the need for secure web service operation and ensures failover support to maintain zero downtime for complex applications. The system facilitates the creation and secure export of custom micro instances as encrypted files, enabling their protected migration.

Abstract: Compounds having activity as kinase inhibitors are provided. The compounds have Structure (I), or a stereoisomer, tautomer, or salt thereof, wherein, R1, R3, and m are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods of use of the same for treatment of diseases and disorders are also provided.

Abstract: Phosphonate conjugates, preferably, bisphosphonate conjugates: methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.

Abstract: A memory includes a bitcell on a substrate, having a bitcell width and a bitcell height and a first access transistor and a second access transistor. The memory includes a first metal layer patterned to form a first pair of wordlines, including a first wordline coupled to a gate of the first access transistor and a second wordline coupled to a gate of the second access transistor. The memory includes a second metal layer patterned to form a pair of second metal layer islands. The pair of second metal layer islands include a first island coupled to the first wordline and a second island coupled to the second wordline. The memory includes a third metal layer patterned to form a pair of third metal layer interconnects, including a first interconnect coupled to the first island and a second interconnect coupled to the second island.

Abstract: A memory is provided with a stack of word line transistors for verifying a word line order and with a stack of bit line transistors for verifying a bit line order. The stack of word line transistors couple between the output terminals of a row decoder and a plurality of word lines. Similarly, the stack of bit line transistors couple between the output terminals of a column multiplexer and a plurality of bit lines.

Abstract: A replica column for bit line tracking of a bitcell array is disclosed that includes just one replica access transistor for each row in the bitcell array. If there are N rows, there are thus N replica access transistors in the replica column, where N is a plural positive integer. The replica column includes no other transistors besides the replica access transistors.

Abstract: The present invention relates to an intelligent, context-aware battery management system embedded within a mobile device that dynamically allocates power resources based on real-time user behavior, system state, and environmental context. It incorporates a smart recognition engine that analyzes sensor-derived telemetry data to compute behavioral deviation scores, enabling the system to anticipate abnormal or emergency-prone conditions. A continuous activity classification module contextualizes user motion and geolocation to inform power policy decisions. Upon detecting significant behavioral anomalies or critically low battery conditions, an emergency mode subsystem is triggered, restricting device operations to essential functionalities while preserving energy for critical communication and navigation tasks. The system also establishes a secure, lightweight emergency communication tunnel for relaying essential metadata, including GPS and behavioral indicators, to predefined response servers.

Abstract: Systems, apparatuses, methods, and computer program products are provided herein. For example, a method may include receiving aviation operations database status data associated with an aviation operations database. In some embodiments, the method may include generating an aviation operations package based on the aviation operations database status data. In some embodiments, the method may include encrypting the aviation operations package using a cloud-based key. In some embodiments, the method may include deploying the aviation operations package to an onboard aviation operations device.

Abstract: A memory includes a periphery separated from one or more banks by a bitcell-to-periphery interface. The periphery includes logic circuits for the reading and writing to bitcells within the neighboring banks. Tap cells for the biasing of the periphery extend across the bitcell-to-periphery interface.

Abstract: The present disclosure provides cellulose/metal composites and their use in removing impurities from liquids, including water. Carboxylated nanocelluloses are combined with metal ions and the resulting composite may be contacted with a liquid, including water, to remove impurities therefrom.

Abstract: An injector device may include an injector handle with a compression mechanism configured to create pressure between the injector handle. Applying pressure to the injector handle may release fluids contained within a fluid containing portion. A loading mechanism may be configured to slide, wherein the loading mechanism may be configured to create a suction force to draw fluids into the fluid containing portion. A first locking mechanism may be positioned between the fluid containing portion and the canula, wherein the first locking mechanism may connect the fluid containing portion to the canula. A second locking mechanism may be positioned between the canula and a needle, wherein the second locking mechanism may connect the canula to the needle, wherein the canula and the needle may include an internal cavity connected the fluid containing portion, wherein the fluids are configured to enter and exit at the needle.

Abstract: The present disclosure provides cellulose/metal composites and their use in removing impurities from liquids, including water. Carboxylated nanocelluloses are combined with metal ions and the resulting composite may be contacted with a liquid, including water, to remove impurities therefrom.

Abstract: The present invention relates to a method of treating cancer in a subject, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a first peptide, wherein the first peptide comprises a first amino acid sequence selected from the group consisting of SEQ ID NOs: 1-33, 52-65, and function-conservative variants thereof. Also provided is a pharmaceutical composition for the treatment of cancer, the pharmaceutical composition comprising: first peptide, wherein the first peptide comprises a first amino acid sequence selected from the group consisting of SEQ ID NOs: 1-33, 52-65, and function-conservative variants thereof.

Abstract: Aspects of the present disclosure provide a filler cell that may be placed next to the active cell to reduce a current-resistor (IR) drop for the active cell. The filler cell includes an active dummy device coupled to a source of a transistor in the active cell and a rail (e.g., a ground rail or a voltage supply rail). The filler cell provides the active cell with at least one additional current path between the source of the transistor and the rail through the active dummy device, which reduces the IR drop between the source of the transistor and the rail.

Abstract: Compounds having activity as inhibitors of ENPP1, CdnP, or both are provided herein. Some embodiments provide compounds having one of the following Structures (I) or (II): or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, wherein R1, R2, R3, R4, R5, R6, R7a, R7b, R7b, R7c, R25, R26, R27a, R27b, R27c, L1, L5, L6, G1, G2, G3 and G6 are as defined herein. This disclosure provides methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds, and methods for treating disorders associated with ENPP1, including uncontrolled cellular proliferation, cancer and virial or bacterial infections in a mammal.

Abstract: Compounds and methods for their preparation and use as therapeutic or prophylactic agents, for example for treatment of bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1).

Abstract: A replica column for bit line tracking of a bitcell array is disclosed that includes just one replica access transistor for each row in the bitcell array. If there are N rows, there are thus N replica access transistors in the replica column, where N is a plural positive integer. The replica column includes no other transistors besides the replica access transistors.

Abstract: The present disclosure includes compounds and methods for treating a subject having a cancer, in particular. Ewing's Sarcoma. A method of treating Ewing's Sarcoma in a subject may comprise the steps of administering to the subject a therapeutically effective amount of a first pharmaceutical composition comprising SP-2577 and administering to the subject a therapeutically effective amount of a second pharmaceutical composition selected from the group consisting of Ruxolitinib, Dasatinib, Nilotinib, Imatinib, Bosutinib, and a drug targeting ABL2 pathway. The drug targeting ABL2 pathway may be an ABL2 knockdown drug, i.e., an ABL2 inhibitor.

Abstract: This disclosure relates generally to recommending tool configurations in machining. The machining tool configuration selection involves the selection of several tool specification parameters concerning the material, geometry and composition of the machining tool. The state-of-the-art methods uses a rule and knowledge-based system to select tool configuration, however these methods do not recommend tool configurations which satisfy customer requirement. Embodiments of the present disclosure uses a hierarchical model which is trained to predict acceptable tool specification parameters for a given requirement by learning the patterns from past tool selection data. Further a probabilistic approach is used to predict the top set of recommendations of tool configurations with a probability score for each prediction. The disclosed method is used for recommending tool configurations in a cylindrical grinding wheel process.